Review Article
Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders
Table 1
Potential molecular targets in schizophrenia.
| | Molecular targets proposed for schizophrenia |
| | Target family | Drug actions |
| | Dopamine receptors | D1 agonists | | D2 antagonists | | D4 antagonists | | D4 agonists |
| | Serotonin receptors | 5-HT1A agonists | | 5-HT1A antagonists | | 5-HT2A antagonists | | 5-HT4 agonists | | 5-HT6 agonists | | 5-HT7 agonists |
| | Muscarinic receptors | M1 agonists | | M4 agonists | | M5 antagonists |
| | GABA receptors | GABA.a (α2) agonists | | GABA.a (α5) antagonists |
| | Adrenergic receptors | α2 adrenergic antagonists |
| | Glutamate receptors | Glycine transporter inhibitors | | mGluR2/3 agonists | | mGluR5 agonists | | NMDA enhancers |
| | Others | Nicotinic α7 agonists | | Nicotinic α4β2 agonists | | Ampakines | | COMT inhibitors |
|
|
